ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Topological Scaffold-Based Trispecific Recombinant Protein-Drug Conjugates for Solid Tumor Eradication.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- N-Acetylcysteine-Functionalized Mixed Micelles Overcome Multiple Intestinal Barriers to Improve Oral Bioavailability and Antioxidant Protection of Imperatorin.Pharmaceutics · 2026Article
- A generalizable covalent car-t platform for solid tumors enabled by oncolytic adenovirus-delivered artificial antigens.Frontiers in immunology · 2026Article
- Topological Scaffold-Based Trispecific Recombinant Protein-Drug Conjugates for Solid Tumor Eradication.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Topology structure of proteins plays vital roles on their bioactivity and property. However, the understanding of how the biological effect of active targeting groups varies with different spatial positions in the recombinant protein scaffold is poor. Here a three trispecific recombinant heterotrimeric proteins and their drug conjugates are reported with a star and linear topology structure prepared by genetically encoded fusion and SpyTag-SpyCatcher technology, which can simultaneously bind the human epidermal growth factor receptor 1 and 2 as well as integrin α
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.